ObEN Debuts World’s First Personal AI Art Concierge at Shanghai K11
ObEN Inc., the artificial intelligence (AI) company that is building a decentralized AI platform for intelligent avatars, today announced the premiere of the first-ever Personal AI (PAI) art docent experience at the museum-retail space Shanghai K11 Art Mall. Bearing the likeness and voice of K11 Founder Adrian Cheng, the AI concierge will guide visitors through K11 Art Museum’s new duo exhibit featuring works from American ceramic artist Betty Woodman and acclaimed Chinese painter Zhao Yang.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180418005462/en/
Adam Zheng, COO and co-founder of ObEN; Adrian Cheng, founder of K11; Nikhil Jain, CEO and co-founder of ObEN (Photo: Business Wire)
“This exhibit introduces visitors to an experience that brings together art and technology in an entirely new and unique dimension,” said Adrian Cheng, founder of K11. “Together with ObEN, we are disrupting the way people navigate the exhibit experience, connecting with them on a deeper, more intimate level and fostering a closer connection between audience, curatorial expression, and artist through technology. We look forward to expanding this immersive experience to other areas within the K11 ecosystem.”
The brainchild of entrepreneur and business innovator Adrian Cheng, K11 is a pioneering multi-faceted brand rooted in culture and interconnected by three core values: art, nature, and people. The K11 Art Mall, featuring flagship locations in Hong Kong, Shanghai, Guangzhou, and Wuhan, is the world’s first museum-retail experience. Consistent with its spirit of innovation, K11 continually seeks and attracts technology partners that help elevate the immersive experience for visitors to its Art Malls, office towers K11 Atelier, and other K11 entities.
The new exhibit is a unique convergence of art and technology, cultures and mediums. From now until June 17, 2018, visitors will be individually guided through the exhibit by Cheng’s PAI, from a smart device bearing an artificial intelligence-based avatar. The first experience of its kind, the PAI concierge will provide visitors with a customized experience, with Cheng’s PAI providing details about select works on display, artist history, and exhibit development.
“This exhibit at K11 showcases the transformative impact PAI can have on industries, including retail and hospitality – providing visitors with more engaging and personalized experiences,” said Nikhil Jain, CEO and co-founder of ObEN. “We are thrilled to partner with K11 to create experiences that complement their unique conglomeration of art, entertainment, and retail.”
The PAI art concierge is powered by ObEN’s Personal AI technology. On the consumer front, the technology allows users to easily create a 3D avatar that looks, sounds, and behaves like them with just one selfie and a brief voice recording from their smartphone. Secured and authenticated on the Project PAI blockchain, ObEN’s PAI provides unprecedented levels of security, data control, and utility. In addition to K11, ObEN also works with leading organizations like S.M. Entertainment, with whom they have a joint venture – AI Stars, the first agency for celebrity Personal AI’s.
ObEN’s Personal AI technology will be available in mid-2018. Learn more at projectpai.com.
About K11 and K11 Investment
K11 was founded in 2008 by entrepreneur and business innovator Adrian Cheng. The pioneering multi-faceted brand is rooted in culture and interconnected by three core values: art, nature, and people. Its ecosystem of business, cultural, technological, and charitable enterprises is a manifestation of the founder's constant search for ways to disrupt stagnant industries and foster cross-cultural dialogues. It spans a wide array of touchpoints: the world’s first museum-retail concept, K11 Art Malls; its state-of-the-art office spaces, K11 Ateliers; its open education platform, K11 Kulture Academy; the curated K11 Design Stores; the Terrarium-inspired transformative retail space K11 Natural; and K11 Art Foundation, China’s first private not-for-profit to incubate Chinese artists and curators. By 2023 the brand will have gained a footprint in 29 projects in nine cities across Greater China.
K11 Investment is the investment arm of New World Development – a Hong Kong-based conglomerate of which Cheng is Executive Vice-chairman and General Manager. Its businesses range from real estate and retail to hospitality. Among K11 Investment’s growing portfolio is DayDayCook, China’s most successful online cooking channel, with over 200 million monthly views. DayDayCook’s first experiential studio opened in Shanghai K11 Art Mall in December 2017. In January 2018, K11 Investment made a US$10 million strategic investment in ObEN to continue the growth of its AI technology.
ObEN is an artificial intelligence (AI) company that is building a decentralized AI platform for intelligent avatars, enabling never before possible social and virtual interactions. The company’s technology allows users to create intelligent 3D avatars that look, sound, and behave like them. Deployed on the Project PAI blockchain, ObEN’s Personal AI (PAI) technology enables users to create, use, and manage their own PAI on a secure, decentralized platform. Founded in 2014, ObEN is a K11, Tencent, Softbank Ventures Korea, and HTC Vive X portfolio company and is located at Idealab in Pasadena, California. To learn more about ObEN, please visit oben.com.
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Zephyr Endobronchial Valves Improve Breathing, Quality of Life and Activity for Severe Emphysema Patients in US Pivotal Trial22.5.2018 20:19 | Tiedote
Pulmonx® Corp. today announced positive one-year results from the U.S. LIBERATE pivotal trial of the Zephyr® Endobronchial Valve, a minimally-invasive treatment for severe emphysema, an advanced form of chronic obstructive pulmonary disease (COPD). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180522006139/en/ Zephyr Endobronchial Valves (Photo: Business Wire) “The LIBERATE Study definitively proves that Zephyr Valves offer clinically meaningful improvements in three important areas for patients – the ability to breathe better, be more active, and enjoy an improved quality of life,” said the study’s lead investigator, Gerard Criner, MD, FACP, FACCP, Chair and Professor of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University. He continued, “All primary and secondary endpoints were met, with Zephyr Valve treatment showing significant improvement for patients across multiple measures of breathing a
Seoul Semiconductor Announces the Availability of a Series of AC LED Modules22.5.2018 19:03 | Tiedote
Seoul Semiconductor, a leading global innovator of LED products and technology, announces a comprehensive series of AC LED modules that use the company’s patented Acrich AC LED technology. The modules are offered in designs from 200 to 10,000 lumens in round, rectangular and linear formats. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180522006054/en/ Seoul Semiconductor Announces the Availability of a Series of AC LED Modules (Photo: Business Wire) These AC modules integrate Seoul Semiconductor’s patented Acrich AC driver technology with the company’s advanced LEDs, enabling the design of compact light fixtures with superior lighting performance, making these modules ideal for a wide range of lighting applications. “Lighting designers who are looking to significantly reduce the size, weight, and volume of their luminaire designs can select one of our standard round, rectangular, or linear AC module designs to develop a co
Medicortex Finland Announces Agreement with Pro-Lab22.5.2018 16:58 | Tiedote
Medicortex Finland Oy announces that it has entered into an agreement with a Canadian company Pro-Lab Diagnostics Inc. Pro-Lab will be responsible for the regulatory process and registration of the ProbTBI™ brain injury detection kit in Canada and UK. Following a brain injury, the diagnostic test will detect in urine and saliva a unique brain injury biomarker which has been discovered and characterized by Medicortex. The agreement gives Pro-Lab exclusive rights for sales in the UK and Canada from which Medicortex will receive royalties. The agreement between the parties is confidential and no other details about the content of the agreement are disclosed. Pro-Lab will be responsible for the clinical validation of the kit prior to the commercial launch in the territories. In addition to the licensing agreement, the parties intend to initiate a development collaboration, the details of which are being discussed currently. “We are very proud that Pro-Lab Diagnostics has chosen to cooperat
ResMed Studies Show Remote Monitoring and Automated Resupply Improve Adherence to PAP Therapy22.5.2018 15:55 | Tiedote
Remote patient monitoring and resupply programs have been shown to improve patient adherence to positive airway pressure (PAP) therapy, according to two separate studies presented by ResMed (NYSE: RMD, ASX: RMD) this week at the ATS 2018 International Conference. Remote monitoring boosts compliance In the first study, medXcloud, a ResMed-assembled group of healthcare key opinion leaders, examined de-identified data of more than 2.6 million U.S. PAP users from ResMed’s world-leading remote monitoring network, AirView. Using this big data approach, researchers observed excellent adherence among patients initiating PAP therapy: 75 percent achieved the CMS compliance threshold.* This rate compares very favorably with that of non-cloud-connected PAP therapy and other chronic medical therapies – both around 50 percent. Plus, the large sample suggests that the findings are generalizable and likely to reflect real-world clinical care. Resupply program boosts long-term compliance In a separate
Asuragen to Launch the AmplideX® PCR/CE DMPK Kit and Present Growing Genetic Testing Portfolio at 2018 European Society of Human Genetics (ESHG) Conference22.5.2018 15:00 | Tiedote
Asuragen, Inc., a molecular diagnostics company delivering high-quality, easy to use products for complex testing in genetics and oncology, today announced the launch of the AmplideX® PCR/CE DMPK Kit* to simplify analysis of repeat expansions within the DMPK gene, which is implicated in myotonic dystrophy type I (DM1), also known as Steinert’s disease. DM1 is an inherited form of muscular dystrophy that affects the muscles as well as multiple other organ systems, and its severity is largely determined by the size of the CTG trinucleotide repeat expansion within the DMPK gene. These expansions commonly extend beyond a thousand CTG repeats and therefore have required the use of cumbersome Southern blot technology to estimate their size. “The AmplideX DMPK Kit represented a significant improvement over our existing process for analyzing large DMPK expansions,” said Doctor Sophie Rondeau, PharmD, PhD, and Professor Jean-Paul Bonnefont, MD, PhD, of the Necker-Enfants Malades Hospital in Par
Phil Brakewell Set to Lead WilsonHCG's Executive Search Efforts Across EMEA; Forbes Ranks WilsonHCG Among Best Executive Recruiting Firms22.5.2018 15:00 | Tiedote
WilsonHCG, global leader and premium provider of innovative talent solutions, further expands its Executive Search division with the appointment of Director Phil Brakewell. Phil, who brings more than 14 years of talent acquisition leadership experience and most recently served as Head of Executive Search for ResourceBank, will be responsible for leading WilsonHCG’s efforts in the EMEA region. Prior to joining ResourceBank, Phil held consultant and resourcing leadership positions at Hitchenor Wakeford and The Caudwell Group – where he was responsible for developing the business internationally and drove innovative search solutions on behalf of a diverse range of clients. “WilsonHCG’s reputation speaks for itself,” said Phil. “WilsonHCG tailors its key service offerings – including Executive Search – to suit individual client needs, and I am thrilled to be part of such a dedicated, innovative team. The new Director position, covering EMEA, demonstrates our commitment to both Executive Se
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme